MDxHealth (NASDAQ:MDXH) Price Target Raised to $9.00

by · The Cerbat Gem

MDxHealth (NASDAQ:MDXH – Get Free Report) had its price objective lifted by equities research analysts at Lake Street Capital from $7.00 to $9.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Lake Street Capital’s target price indicates a potential upside of 121.67% from the company’s current price.

Other research analysts have also recently issued reports about the company. BTIG Research upped their price objective on MDxHealth from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Thursday. Craig Hallum began coverage on MDxHealth in a report on Thursday, July 17th. They set a “buy” rating and a $8.00 price objective on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of MDxHealth in a research note on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of MDxHealth to a “hold” rating in a research report on Saturday, August 30th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, MDxHealth has an average rating of “Moderate Buy” and an average price target of $7.75.

Get Our Latest Stock Analysis on MDXH

MDxHealth Trading Down 1.5%

Shares of MDXH traded down $0.06 during midday trading on Thursday, hitting $4.06. 195,657 shares of the stock were exchanged, compared to its average volume of 120,087. MDxHealth has a 52-week low of $1.35 and a 52-week high of $5.33. The company has a debt-to-equity ratio of 13.81, a quick ratio of 1.22 and a current ratio of 1.31. The stock has a fifty day simple moving average of $4.31 and a 200 day simple moving average of $3.04. The firm has a market cap of $191.99 million, a P/E ratio of -4.61 and a beta of 1.68.

MDxHealth (NASDAQ:MDXH – Get Free Report) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.04). The business had revenue of $27.43 million during the quarter, compared to analysts’ expectations of $24.11 million. MDxHealth had a negative net margin of 34.98% and a negative return on equity of 374.98%. MDxHealth has set its FY 2025 guidance at EPS. On average, research analysts anticipate that MDxHealth will post -1.15 EPS for the current fiscal year.

Hedge Funds Weigh In On MDxHealth

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Perkins Capital Management Inc. boosted its stake in shares of MDxHealth by 20.1% during the 1st quarter. Perkins Capital Management Inc. now owns 1,181,475 shares of the company’s stock worth $1,678,000 after acquiring an additional 198,000 shares in the last quarter. Delta Investment Management LLC lifted its holdings in shares of MDxHealth by 459.1% during the first quarter. Delta Investment Management LLC now owns 190,100 shares of the company’s stock valued at $270,000 after purchasing an additional 156,100 shares during the last quarter. AWM Investment Company Inc. boosted its position in shares of MDxHealth by 10.6% in the 1st quarter. AWM Investment Company Inc. now owns 5,221,282 shares of the company’s stock valued at $7,414,000 after purchasing an additional 499,992 shares during the period. FreeGulliver LLC purchased a new position in MDxHealth in the 2nd quarter worth about $273,000. Finally, Calamos Advisors LLC acquired a new stake in MDxHealth during the 3rd quarter worth about $305,000.

MDxHealth Company Profile

(Get Free Report)

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.

Read More